Details:
Under the agreement, Debiopharm will boost its ADC oncology pipeline through SunRock’s antibody portfolio, including SRB21, an anti-HER3-HER2 bispecific, integrating Debiopharm’s Multilink™ & AbYlink™ technologies to create innovative antibody drug conjugates (ADCs).
Lead Product(s): SRB21
Therapeutic Area: Oncology Product Name: SRB21
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Debiopharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 21, 2023
Details:
Under the agreement, Ellipses has been granted global rights to develop and commercialise EP0017 and will assume the full cost and responsibility for the remaining pre-clinical and clinical development of the compound.
Lead Product(s): SRB22
Therapeutic Area: Oncology Product Name: EP0017
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Ellipses Pharma Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 25, 2022
Details:
EC-8042 (redesignated AIT-102), is a targeted cancer therapy that inhibits the activity of SWI/SNF in certain tumors where SWI/SNF is mutated (such as Rhabdoid tumors) and in other tumors where SWI/SNF associates with oncogenic transcription factors.
Lead Product(s): AIT-102
Therapeutic Area: Oncology Product Name: AIT-102
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: AI Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 25, 2022
Details:
These funds, together with Oncomatryx recurring revenues from its licensing agreements with international biopharmaceutical companies, will be used for the clinical development of additional ADCs of Oncomatryx tumour-microenvironment pipeline including OMTX705.
Lead Product(s): OMTX705
Therapeutic Area: Oncology Product Name: OMTX705
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $16.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 22, 2022
Details:
The financing will allow Ona Therapeutics to complete the pre-clinical development in a variety of tumor types and to move its lead candidate into first clinical studies in patients with metastatic cancer in 2023.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Fund+
Deal Size: $33.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 16, 2020